期刊文献+

MDM2启动子区309位点基因多态性与乳腺癌风险的关系 被引量:7

Association between MDM2 SNP309 Polymorphism and Breast Cancer Risk in Chinese Women
下载PDF
导出
摘要 目的:采用病例-对照研究检测MDM2启动子区309位点T>G单核苷酸多态(SNP309)在中国女性人群中的频率分布,分析其与中国女性乳腺癌发病风险的关系。方法:提取病例组698例原发性乳腺癌患者及对照组525例健康人的外周血单核细胞DNA,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析法,检测MDM2启动子区309位点基因多态性,确定此位点三种基因型,即T/T、T/G、G/C基因型。统计分析病例组和对照组人群MDM2 SNP309各基因型频率分布,及各基因型与乳腺癌发病风险的相关性。结果:在研究的病例组与对照组整体人群中,经年龄、月经状态、家族史及生育史等因素校正后,与MDM2 SNP309 T/T基因型比较,T/G型及G/G型与乳腺癌的发病风险无显著相关性(T/G,adjusted OR=1.2,95%CI:O.8~1.6,P=0.30;G/G,adiusted OR=I.0,95%CI:0.7~1.5,P=0.88)。进一步分层分析后显示:在绝经后人群中,与T/T基因型比较,T/G基因型及G/G基因型显著增加乳腺癌的发病风险(T/G,adjusted OR=1.8,95%CI:1.2~3.0,P=0.011;G/G,adiusted OR=1.9,95%CI:1.2~33,P=0.014)。提示绝经后人群携带T/G型、G/G型者比携带T/T基因型者患乳腺癌的风险分别升高约1.8、1.9倍。在绝经前人群中,各基因型与乳腺癌的发病风险无显著相关性(P>0.05)。结论:MDM2启动子309位点突变型G等位基因携带者显著增加绝经后女性乳腺癌的发病风险。 Objective: To investigate the correlation of MDM2 SNP309 polymorphism with breast cancer risk in Chinese women. Methods: The polymorphism of MDM2 SNP309 was detected by PCR-restriction fragment length polymorphisms assay (PCR-RFLP) in 698 women with primary breast cancer and 525 healthy controls. Results: Compared with the T/T genotype, the G allele (T/G or G/G) was not associated with an increased risk of breast cancer in the entire population studied (T/G, adjusted OR=1.2, 95% CI: 0.8-1.6, P= 0.30; G/G, adjusted OR=1.0, 95% CI: 0.7 - 1.5, P=0.88). Among postmenopausal women, the G allele (T/G or G/G) was significantly associated with an increased risk of breast cancer (T/G, adjusted OR=1.8, 95% CI: 1.2-3.0, P=0.011; G/G, adjusted OR=1.9, 95% CI: 1.2-3.3, P=0.014). But this association was not observed among premenopausal women. Conclusion: MDM2 SNP309 heterozygous T/G genotype and homozygous mutant GIG genotype increase breast cancer risk in postmenopausal Chinese women.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2010年第3期131-133,共3页 Chinese Journal of Clinical Oncology
基金 国家自然科学基金资助(编号:30672419)~~
关键词 MDM2 单核苷酸多态性 乳腺癌 发病风险 MDM2 Single nucleotide polymorphism Breast cancer Risk
  • 相关文献

参考文献11

  • 1Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans[J]. Cell, 2004, 119(5): 591-602.
  • 2Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture[J]. Cancer Res, 1999, 59(1): 1-7.
  • 3Ma H, Hu Z, Zhai X, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population[I]. Cancer Lett, 2006, 240(2): 261-267.
  • 4Schrnidt MK, Reincke S, Broeks A, et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium[J]. Cancer Res, 2007, 67(19): 9584-9590.
  • 5Millikan RC, Heard K, Winkel S, et al. No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites[]]. Cancer Epidemiol Biomarkers Prey, 2006, 15(1): 175-177.
  • 6Lum SS, Chua HW, Li H, et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population[J].Carcinogenesis, 2008, 29(4): 754-761.
  • 7Sun YF, Leu .JD, Chen SM, et al. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer[J]. BMc Cancer, 2009, 9:13.
  • 8Singh V, Rastogi N, Mathur N, et al. Association of polymorphism in MDM2 and p53 genes with breast cancer risk in Indian women[J]. Ann Epidemiol, 2008, 18(1): 48-57.
  • 9Ueda M, Yamamoto M, Nunobiki O, et al. Murine double-minute 2 homolog single nudeodde polymorphism 309 and the risk of gynecologic cancer[J]. Hum Cell, 2009, 22(2): 49-54.
  • 10Hori M, ShimazakiJ, Inagawa S, et al. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer [J]. Breast Cancer Res Treat, 2002, 71(1): 77-83.

同被引文献73

  • 1宋传贵,傅芳萌,吴雪英,林舜国,王川.MDM2基因SNP309可能与早发性乳腺癌易感性无关:福建病例-对照研究[J].中国癌症杂志,2011,21(4):262-265. 被引量:1
  • 2宋丽萍,邱曙东.P53-mdm2相互作用与肿瘤治疗策略[J].中国肿瘤生物治疗杂志,2005,12(4):303-305. 被引量:2
  • 3熊首先,朱尤庆,何军.MDM2和p53在大肠癌组织中的表达及其意义[J].长江大学学报(自科版)(下旬),2007,4(1):11-13. 被引量:6
  • 4Bond G L, Hu W, Bond E E, et al. A single nucleotide polymor- phism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [ J ]. Cell, 2004,119(5) :591- 602.
  • 5Bond G L, Hirshfield K M, Kirchhoff T, et al. MDM2 SNP309 ac- celerates tumor formation in a gender-specific and hormone-de- pendent manner [ J ]. Cancer Res,2006,66 ( 10 ) :5104-5110.
  • 6Firoz E F, Warycha M, Zakrzewski J, et al. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma[ J ]. Clin Cancer Res, 2009,15 ( 7 ) :2573-2580.
  • 7Joshi A M, Budhathoki S, Ohnaka K,et al. TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the fukuoka colorectal cancer study [J]. Jpn J Clin Oncol, 2011,41 ( 2 ) : 232- 238.
  • 8Ma H, Hu Z,Zhai X,et al. Potymorphisms in the MDM2 promoter and risk of breast cancer a case-control analysis in a Chinese popu- lation[ J]. Cancer Lett,2006,240(2) :261-267.
  • 9Nakashima M, Kondo S, Shimizu Y ,et al. Impact of MDM2 single nucleotide polynmrphism on tumor onset in head and neck squain- ous cell carcinoma [J]. Acta Otolarvngol, 2008,128 ( 7 ) : 808-813.
  • 10Ohmiya N,Taguchi A, Mabuchi N,et al. MDM2 promuter poly- morphism is asociated with both an increased susceptibility to gas- tric carcinoma and poor prognosis [ J ]. J Clin Oncol, 2006,24 (27) :4434- 4440.

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部